Author:
O’Neill Ciara E.,Sun Kai,Sundararaman Sugunapriyadharshini,Chang Jenny C.,Glynn Sharon A.
Abstract
The human epidermal growth factor receptor (HER) family consists of four members, activated by two families of ligands. They are known for mediating cell–cell interactions in organogenesis, and their deregulation has been associated with various cancers, including breast and esophageal cancers. In particular, aberrant epidermal growth factor receptor (EGFR) and HER2 signaling drive disease progression and result in poorer patient outcomes. Nitric oxide (NO) has been proposed as an alternative activator of the HER family and may play a role in this aberrant activation due to its ability to induce s-nitrosation and phosphorylation of the EGFR. This review discusses the potential impact of NO on HER family activation and downstream signaling, along with its role in the efficacy of therapeutics targeting the family.
Reference286 articles.
1. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity;Akiyama;Sci. (New York, N.Y.),1986
2. Identification of S-nitroso-CoA reductases that regulate protein S-nitrosylation;Anand;Proc. Natl. Acad. Sci. U. S. A.,2014
3. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes;Andl;Am. J. Physiology-Gastrointestinal Liver Physiology,2004
4. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth;Andrechek;Oncogene,2005
5. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells;Anido;Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res.,2003
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献